{"id":133913,"date":"2022-09-15T08:54:30","date_gmt":"2022-09-15T12:54:30","guid":{"rendered":"https:\/\/44.250.171.167\/?p=133913"},"modified":"2022-10-06T04:57:22","modified_gmt":"2022-10-06T08:57:22","slug":"balaxi-pharmaceuticals-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/balaxi-pharmaceuticals-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Balaxi Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Balaxi Pharmaceuticals Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/BALAXI\/\">BALAXI<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:06:25] Archana Gude with IDBI asked about the sustainable EBITDA margin expectation going forward. Ashish Maheshwari MD replied that EBITDA margins the company will be seeing in the current range of 19% only.<\/li>\n<\/ul>\n<ul>\n<li>[00:07:46] Archana Gude with IDB enquired that once BALAXI\u2019s plants will be operational in Hyderabad, how the mix will be going forward and the incremental margin improvement in 2-3 years. Ashish Maheshwari MD said that in branded the company has grown from 30% to 35% in FY22 and the target is to take it to 47-48% in next 3 years and margins will go up by 10-12%.<\/li>\n<\/ul>\n<ul>\n<li>[00:10:13] Sunny Agrawal of SBICAPS Securities enquired about company\u2019s market share and the competitors in existing and new markets. Ashish Maheshwari MD said that as per the company\u2019s market intelligence, it\u2019s in the top 3 in Angola, in Dominican Republic number 1 and Guatemala number 2. \u00a0Competitors in Africa are Shalina and Prince Farma. In LatAm, the key competitor is Caplin Point.<\/li>\n<\/ul>\n<ul>\n<li>[00:12:51] Avinash Gorakshakar from ProfitMart asked about the volume increase in 1Q23. Ashish Maheshwari MD replied that it\u2019s 42% growth, but added that it\u2019s not strictly comparable to the previous quarter as Angola sales is the differentiator. Volume growth in LatAm in 1Q23 was around 30%.<\/li>\n<\/ul>\n<ul>\n<li>[00:14:19] Avinash Gorakshakar with ProfitMart asked if the GM growth driven by cross currency translation in 1Q23 will continue going forward. Ashish Maheshwari MD clarified that the India rupee generally depreciates against USD. However generally, BALAXI sees 1.8-2% in exchange rate profits. In 1Q23, BALAXI saw extra exchange rate profit coming in from Angola, which won\u2019t be the case in future.<\/li>\n<\/ul>\n<ul>\n<li>[00:16:43] \u00a0Avinash Gorakshakar with ProfitMart asked about the company\u2019s opinion on the state of the market in FY23, if the healthy growth is expected to continue. Ashish Maheshwari MD said LatAm markets are expected to see at least 40-42% growth in revenue.<\/li>\n<\/ul>\n<ul>\n<li>[00:19:29] Alisha Mahawla from Envision Capital enquired about the newer geographies where registrations caused upfronting of cost. Ashish Maheshwari MD replied the newer geographies were El Salvador, Honduras and Nicaragua. Going forward, BALAXI has registered the company is Ecuador and Chile.<\/li>\n<\/ul>\n<ul>\n<li>[00:27:56] Keshav Kumar of RakSan Investors asked what percentage of company\u2019s sourcing is from China currently. Ashish Maheshwari MD replied that sourcing is majorly from India currently and about 30% or less comes from China.<\/li>\n<\/ul>\n<ul>\n<li>[00:34:23] Chinmay Garg with Dron Capital asked about the working capital cycle in Angola. Amol Mantri CFO answered that in Angola it\u2019s about 150-160 days.<\/li>\n<\/ul>\n<ul>\n<li>[00:37:31] Chirag asked about future margins; once the manufacturing is in place, how will that impact margins. Ashish Maheshwari MD said that currently about 60% of manufacturing is done in-house and rest outsourced. On this, BALAXI expects 8-10% increase in margins due to own manufacturing, translating to 4-5% on a total revenue basis.<\/li>\n<\/ul>\n<ul>\n<li>[00:40:20] Harsh Beria asked about the cost structure for the marketing unit in LatAm markets. Ashish Maheshwari MD answered that cost structure for LatAm is very lean when compared to Angola and said Guatemala EBITDA looked lower due to promotions.<\/li>\n<\/ul>\n<ul>\n<li>[00:42:42] Harsh Beria enquired about the network of wholesales; how many does the company deal with in LatAm and Angola. Amol Mantri CFO said in LatAm the company is working with around 80-85 wholesalers and distributors. And in Guatemala, BALAXI is working with around 16 wholesalers and distributors. In Angola, it\u2019s around 1,000.<\/li>\n<\/ul>\n<ul>\n<li>[00:46:21] Jitendra Upadhyay of Bonanza Portfolio asked about incremental revenue from new project. \u00a0Ashish Maheshwari MD said that it\u2019s a backward integration project and from the new projects, revenue will increase but it will give more in terms of profitability and control over quality of BALAXI products.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Balaxi Pharmaceuticals Ltd (BALAXI) Q1 FY23 Earnings Concall Q&amp;A Highlights: [00:06:25] Archana Gude with IDBI asked about the sustainable EBITDA margin expectation going forward. Ashish Maheshwari MD replied that EBITDA margins the company will be seeing in the current range of 19% only. [00:07:46] Archana Gude with IDB enquired that once BALAXI\u2019s [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Balaxi Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights #BALAXI #Q1 #FY23 #Earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-133913","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":136269,"url":"https:\/\/alphastreet.com\/india\/balaxi-pharmaceuticals-ltd-balaxi-q1-fy23-earnings-concall-transcript\/","url_meta":{"origin":133913,"position":0},"title":"Balaxi Pharmaceuticals Ltd (BALAXI) Q1 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"August 18, 2022","format":false,"excerpt":"Balaxi Pharmaceuticals Ltd (NSE:BALAXI) Q1 FY23 Earnings Concall dated Aug. 18, 2022 Corporate Participants: Ashish Maheshwari -- Managing Director Pranav Maheshwari -- Vice President Business Development Amol Mantri -- Chief Financial Officer Analysts: Archana Gude -- IDBI -- Analyst Sunny Agarwal -- SBI Securities -- Analyst Avinash Gorakshakar -- Profitmart\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139687,"url":"https:\/\/alphastreet.com\/india\/pondy-oxides-and-chemicals-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133913,"position":1},"title":"Pondy Oxides and Chemicals Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 1, 2023","format":false,"excerpt":"https:\/\/youtu.be\/XcWVyR2YnNo Key highlights from Pondy Oxides and Chemicals Ltd (532626) Q3 FY23 Earnings Concall Management Update: [00:07:52]POCL said that during 3Q23, aluminum production was commenced, as well as trial production in plastics. [00:09:42] The company said it was also awarded the order to take over Harsha Exito Engineering Pvt. Ltd.,\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133197,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133913,"position":2},"title":"Divi&#8217;s Laboratories Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 15, 2022","format":false,"excerpt":"https:\/\/youtu.be\/EPaxfKgyoZQ Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Q&A Highlights: Tushar Manudhane from Motilal Oswal asked about the stable sales in the generic side for the past 3 quarters, if capacity expansion will increase sales in coming quarters. Murali Divi MD said that with the expansion,\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136392,"url":"https:\/\/alphastreet.com\/india\/jubilant-foodworks-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133913,"position":3},"title":"Jubilant FoodWorks Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2022","format":false,"excerpt":"https:\/\/youtu.be\/eQd73udCwH8 Key highlights from Jubilant FoodWorks Limited (JUBLFOOD) Q2 FY23 Earnings Concall Management Update: [00:03:56] JUBLFOOD added 76 new stores and entered 22 new cities in India. Overall, the company opened 134 new Domino's stores in the first half and said it is well on track to achieve the store\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133714,"url":"https:\/\/alphastreet.com\/india\/grasim-industries-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133913,"position":4},"title":"Grasim Industries Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"September 2, 2022","format":false,"excerpt":"https:\/\/youtu.be\/xRtcn91-REs Key highlights from Grasim Industries Limited (GRASIM) Q1 FY23 Earnings Concall Management Update: [00:02:49] GRASIM said its Chlor-Alkali and Textile businesses reported highest ever quarterly EBITDA, driven by better realization and sales volume. [00:03:43] GRASIM said it expects FY23 capex guidance of INR3,117 crores for the existing lines of\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133434,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133913,"position":5},"title":"Zydus Lifesciences Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/R4mbpNYrIhE Key highlights from Zydus Lifesciences Ltd (ZYDUSLIFE) Q1 FY23 Earnings Concall Q&A Highlights: Neha enquired about the drivers of strong growth in the US business QonQ and if it\u2019s sustainable. Sharvil Patel MD replied that there are no one-offs in the overall numbers. The sequential growth was due to\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=133913"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=133913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=133913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=133913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}